It has been suggested that tyrosine kinase activity participates in the regulation of signal transduction associated with angiotensin II (Ang II)-induced pharmaco-mechanical coupling in rat aortic smooth muscle. We further tested the effects of genistein, a tyrosine-kinase inhibitor, and its inactive analogue, daidzein, on angiotensin
Introduction
It is generally accepted that the renin-angiotensin system (RAS) exerts its effects predominantly via angiotensin II (Ang II). Although it was originally thought that Ang II acted only as a blood-borne hormone, multiple lines of evidence support the existence of a local vascular RAS independent of the circulating system. Renin-like enzymes have been described in several tissues, as well as alternative pathways for the generation of angiotensin peptides. [1] [2] [3] Angiotensin I (Ang I) is considered devoid of intrinsic biological activity. Therefore, in endothelium-denuded aortic rings, Ang I and Ang II induced identical contractions. 4 Since captopril, an inhibitor of angiotensin-converting enzyme (ACE), blocked these effects, it was considered that Ang I-induced contractions were due to Ang II generation. Both angiotensin III (Ang III) and angiotensin IV (Ang IV) are known to be important degradation products of Ang II. 5 Ang III and Ang IV each elicited concentration-dependent contractions of rat aortic rings, with a similar maximal effect as Ang II, indicating similar efficacies of these three peptides in this preparation. [5] [6] [7] [8] Moreover, accumulating evidence suggests that angiotensin (1) (2) (3) (4) (5) (6) (7) [Ang (1) (2) (3) (4) (5) (6) (7) ] is also an important component of the RAS. 9 Classically, Ang II initiates cellular responses by activation of type 1 (AT 1 ) and type 2 (AT 2 ) angiotensin receptors. Ang III seems to share receptors with Ang II, although it may also activate a specific receptor site in the adrenal cortex. 10 Ang IV and Ang(1-7) recognise the AT 1 -and AT 2 -receptors with lower affinity than Ang II and, in addition, have their own receptors, that mediate effects which are often opposed to those of Ang II. Thus, new putative subtypes of AT receptors, AT 3, 11 AT 4 12 and AT 1-7 9, 13 were described. It is generally believed 14 that the vasoconstrictor response to Ang II in rat aorta involves only the activation of AT 1receptors located on vascular smooth muscle.
In this preparation, upon binding to its specific AT 1 -receptor, Ang II initiates a series of biochemical events that result in the accumulation of inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol (DAG). 15 IP 3 stimulates the mobilisation of Ca 2+ from intracellular stores, 16 while DAG stimulates protein kinase C (PKC).These Ang II-induced events are mediated through the activation of the Keywords: angiotensin I, angiotensin II, angiotensin III, angiotensin IV, tyrosine kinase activity, aorta, rat β-isoform of phospholipase C (PLC-β). Some recent results suggest a novel mechanism for IP 3 generation in vascular smooth muscle cells by Ang II, that involves tyrosine phosphorylation and activation of PLC-γ1. 17 This phosphorylation is rapid, occurring within 30 seconds of exposure to Ang II. Presumably, in this situation,Ang II stimulates a non-receptor or cytosolic protein tyrosine kinase.
It has been suggested that tyrosine kinase participates in the regulation of signal transduction associated with pharmaco-mechanical coupling in smooth muscle such as canine carotid arterial smooth muscle, guinea pig taenia coli and guinea pig mesenteric microvessels. 18 Moreover, the actions of Ang II, as well as the contractile actions of a variety of other G-protein-coupled agonists in vascular smooth muscle (rat aorta) were inhibited by the tyrosine kinase inhibitor, genistein. 19 In the present study, we used the isolated rat aorta as a model to characterise the effects of genistein on the contractile response to angiotensin peptides [Ang I, Ang III, Ang IV and Ang(1-7)]-induced contractions, as compared with responses to Ang II.
Tyrosine phosphorylation may require extracellular Ca 2+ . 20 For this reason, we also tested the effects of tyrosine kinase inhibition by genistein on the association of extracellular Ca 2+ and the contractile effects of angiotensin peptides in rat aortic ring preparations.
Materials and methods

Preparation of the rat aorta
Male Wistar rats (150-200 g body weight) were decapitated and exsanguinated. The descending thoracic aorta was rapidly removed and cleaned of connective tissue in Krebs-Henseleit solution (at 37 o C) of the following composition (mM) : NaCl 118, KCl 4.8, CaCl 2 2.5, MgSO 4 1.6, KH 2 PO 4 1.2, NaHCO 3 25, glucose 5.5; pH 7.4. Each aorta, without endothelium (removed by gentle rubbing with a smooth softwood stick), was cut into rings, 2 mm wide, to avoid the inhibitory role of functional endothelium to angiotensin peptides. Individual rings were then mounted between hooks in 2 ml tissue chambers containing the Krebs-Henseleit solution at 37°C, bubbled continuously with 95% O 2 and 5% CO 2 . A resting tension of 2 g was applied to each ring, then allowed to equilibrate for 1 hour before the start of the experiment. Changes in isometric tension were displayed using a force transducer, a PC-LPM-16 multifunctional I/O board and NiDaqWin software (National Instruments). The study conformed to the Guide for the Care and Use of Laboratory Animals published in 1996 by the U.S. National Academy of Sciences and approved by the Ethics Committee of the University of Medicine and Pharmacy "Gr. T.Popa" Iasi.
Experimental design
The experiments were performed only in endothelium-denuded preparations with a stable baseline tension. After the equilibration period, the rat aorta rings were repeatedly stimulated with 40 mM K + until two consecutive contractions which differed by less than 10% were obtained (testing at the same time the viability). In most cases, a maximal contractile response ranging from 0.9-1.4 g (9-14 mN) could be induced. The amplitude of the last 40 mM K + -induced contraction was considered as the control (100%) for further treatments. The potassium solution had the same composition as the Krebs-Henseleit buffer used, except that NaCl had been completely replaced by an equimolar concentration of KCl. Preparations with a response bellow 0.6 g were considered insufficiently viable and discarded. Thereafter, the experimental protocols were performed. The test compounds were added to the organ bath in a maximal volume of 20 µl from stock solutions.
To avoid tachyphylaxis, only a single response for an angiotensin peptide was obtained in each ring preparation. Appropriate controls were run at the same time in different rings obtained from the same aorta.The antagonists (saralasin, nifedipine, genistein and daidzein) were added 15 minutes before the addition of agonists.
In experiments using Ca 2+ -free Krebs-Henseleit buffered solution (no CaCl 2 and 2.5 mM EGTA added) the normal extracellular Ca 2+ concentration was restored by addition of 5 mM CaCl 2 .
At the end of the experiment, after the drugs had been washed out, carbachol 10 -5 M was added when a maximal response to phenylephrine (1 µM) had been obtained, in order to assess the presence or absence of functional endothelium.
Expression of results and statistical analysis
The results are expressed as the percentage of the control contraction (K + , 40 mM) (mean±SEM, n=6). Rings from different animals were used to obtain the number of experiments. From each animal, a ring was used only once in experimental procedures. Statistical significance was tested using one-way analysis of variance (ANOVA), with Student-Newman-Keuls method (SigmaStat software, Jandel Corporation). p<0.05 was considered statistically significant.
Drugs used
Ang I, Ang II, Ang III, Ang IV, Ang(1-7), saralasin [(Sar 1 ,Val 5 ,Ala 8 )Ang II], nifedipine, genistein, daidzein, captopril and carbachol were all obtained from Sigma. All other compounds used were of analytical grade. Angiotensin peptides were stored frozen as aliquots, which were defrosted as required on the day of experiment. Dilutions of all drugs were made in Krebs-Henseleit solution.
Results
The contractile effects of angiotensin peptides are presented in Figure 1 and Table 1 .We administered concentrations of angiotensin peptides that induced very similar contractions in isolated rat aorta. Thus, administration of 8 x 10 -8 M Ang II induced a contraction of 21±2.06% (n=6, *p<0.05, as compared with control contraction induced by K + 40 mM). 6 x 10 -7 M Ang I induced contractions of 21.32±1.25%, 10 -6 M Ang III to 21.83±2.83% and 10 -5 M Ang IV to 21.58±1.92% of the control contraction (n=6, *p<0.05). Ang(1-7), 10 -5 M, did not induce rat aortic ring contractions. The highest concentrations (10 -4 M) contracted the aorta by only 5.08±1.73% (n=6, data not shown). In order to verify whether all the contractile activity of Ang I was associated with Ang II or Ang III transformation, we administered captopril, 1 µM and 10 µM, as pre-treatment. Both concentrations of captopril blocked only 35% (average value, n=6) of Ang Iinduced contraction (personal observation, data not shown).
To test the subtype of angiotensin receptor involved in these contractions, we administered 10 µM saralasin, [(Sar 1 ,Val 5 ,Ala 8 )Ang II], a peptide membrane AT 1 -receptor antagonist, as pre-treat-ment ( Figure 2 and Table 1 ). Saralasin strongly blocked both Ang II-and Ang I-induced contractions. In contrast, it inhibited Ang III and Ang IV contractile effects to a lesser extent. Thus, the order of saralasin inhibitory potency is: Ang II≈ Ang I>Ang III>Ang IV.
In order to verify the involvement of tyrosine kinase activity in the angiotensin peptide-induced contraction, we used 10 µM genistein, a protein kinase inhibitor with a strong preference for tyrosine-specific kinases ( Figure 3 and Table 1 ). Genistein partially inhibited Ang II-and Ang Iinduced contractions. The genistein-induced inhibition was more evident on Ang III-and especially Table 1 Contractile effects of Ang II, Ang I, Ang III and Ang IV in endothelium-denuded rat aortic ring preparations and in preparations pre-treated with saralasin (10 µM), genistein (10 µM), daidzein (10 µM), nifedipine (1 µM), Ca 2+ -free buffer and Ca 2+ -free buffer + genistein (10 µM). marked on Ang IV-induced contraction.The order of genistein inhibitory potency is: Ang IV>Ang III>Ang II>Ang I. At the same time, the presence of genistein as pre-treatment reduced not only the intensity, but also the duration of all the tested angiotensin peptide-induced contractions.To confirm the effects of genistein, we also tested daidzein, 10 µM, an analogue of genistein which is devoid of tyrosine kinase inhibitory activity (Table  1) . Daidzein had no significant inhibitory actions on the contractile effects of angiotensin peptides in rat isolated aortic rings.
Pre-treatment with 1 µM nifedipine, which blocks plasma membrane L-type Ca 2+ channels, strongly inhibited Ang IV-and Ang III-induced contractions ( Figure 4 and Table 1 ), while also reducing their duration.These effects are in contrast to the slight inhibition of Ang II-and Ang I-contractile effects. Thus, the potency of nifedipine inhibitory action is: Ang IV≈Ang III>Ang I>Ang II.
Finally, we tested the contractile effects of angiotensin peptides in Ca 2+ -free solution.As seen in Table 1 , angiotensin peptides induced weak contractions when compared with their effects in Ca 2+ -containing buffer. These contractile effects, which were also phasic, (data not shown, personal observations) were not significantly modified by pre-treatment with 10 µM genistein for 15 minutes in Ca 2+ -free solution (Table 1) . Daidzein, 10 µM, also had no significant effect on these angiotensin peptides-induced contractions (data not shown, personal observation).
For comparison, we also sought to determine the effects of genistein and daidzein on depolarisationinduced contractions (K + 40 mM), which are known to be mediated by Ca 2+ influx through plasma membrane L-type Ca 2+ channels. This was done to verify a direct effect of genistein on this type of Ca 2+ channel. Genistein, but not daidzein, reduced depolarisa-tion-induced contractile effects in isolated rat aorta rings by only 10.75±1.74% (n=6; personal observation, data not shown, not statistically significant).
Discussion
Ang II is the biologically active component via which the RAS exerts its many and varied effects on target cells. 21 Furthermore, Ang II receptors are present in several organs in which the peptide can elicit contractile responses that are not physiologically controlled by circulating Ang II. 10 In addition, there is evidence that other angiotensin peptides are biologically active in several tissues. 22 Our data show that almost all active angiotensin peptides contract isolated rat aorta rings, with the exception of Ang(1-7).To avoid the consequences of tachyphylaxis, only a single submaximal optimal response for an angiotensin peptide was obtained in each ring preparation. In our opinion, this procedure is closer to normal physiological conditions, although we recognise that dose-response curves to angiotensin peptides may give more detailed pharmacological information. In terms of contractile effects, the most potent peptide was Ang II, whereas Ang I and Ang III were almost equipotent and Ang IV was the least potent. Similar observations have been obtained in several tissues and species. Thus, Ang III and Ang IV were shown to induce similar maximal effects as Ang II, indicating similar efficacies of these three peptides in rat aortic rings. 5, 7 Ang III was 3-4 times less potent than Ang II in rat aorta, 7 as well as in rat uterus, 23 but approximately 38-fold less potent in rabbit aortic rings. 5 In our study, we observed that, in rat aortic ring preparations, Ang III was approximately 12.5-fold less potent than Ang II. Generally, it is thought that the deletion of the amino-terminal residue of Ang II to produce Ang III significantly reduces the receptor binding affinity in most tissues.Ang III has been proposed to exert similar, but weaker, effects to Ang II. 5, 10, 24 In addition, Ang III can be formed by an alternative pathway, which does not involve the formation of Ang II, via the nonapeptide, des-Asp 1 -Ang I, which is then acted upon by ACE to form Ang III. 25 It has also been reported that rat aorta degrades Ang I almost exclusively to des-Asp 1 -Ang I, rather than to Ang II. 26 Thus,Ang III may be an important biologically-active component of the RAS, at least in rat vasculature. The contractile effects of Ang III in isolated rat aorta demonstrated in this study are in accordance with the above data. Ang IV is formed by the deletion of arginine at the N-terminus of Ang III. As already mentioned, Ang IV induced similar maximal effects to Ang II in rat aortic rings, 7 as well as in the pulmonary vessels of cat 6 and rat. 8 Ang IV was found to be a thousand times less potent than Ang II in rat aortic rings, 7 although the above studies 6,8 indicate a smaller difference in potency between the two peptides. In our study, we observed Ang IV to be 125-fold less potent than Ang II in aortic ring preparations.All these data show that Ang IV may induce contractile effects in some vascular preparations, and may be a potent biologically-active metabolite of Ang II, manifesting vasoconstrictor properties at the level of rat endothelium-denuded aorta. This is in contrast to previous results showing that Ang IV acts as a vasodilator and increases blood flow in the kidney and the brain. 27 Surprisingly, in our study, Ang I was only 7.5fold less potent than Ang II and slightly more potent than Ang III (1.66-fold), though these results show a similar tendency to those previously described. 28 Ang I, the precursor molecule of Ang II, is actually considered devoid of biological activity. It was also shown that, in vascular smooth muscle cells, as well as in endothelium-denuded aortic rings, Ang I and Ang II induced identical contractions. 4 However, in the presence of the ACE inhibitor, captopril, the contractile effect of this peptide was strongly decreased. In our study, not all the contractile activity of Ang I was mediated by Ang II, since captopril only partially blocked Ang Iinduced contractions. These results suggest the involvement of other alternative pathways of Ang I metabolism. 25, 26 A series of preliminary data involves the pathway controlled by aminopeptidase A (personal observation, data not shown), at least in endothelium-denuded rat aorta rings.
An extremely important observation is that all the angiotensin peptides induced a transient contraction, consistent with the rapid termination and desensitisation of many receptor responses. 29 Ang II exerts its actions through two major subtypes of AT receptors,AT 1 and AT 2 .These receptors share a common seven-loop transmembrane structure with other G-protein-coupled receptors, but their functions and tissue distributions differ. 30 In rats and mice, the cloned AT 1 -receptor has AT 1a and AT 1b subtypes.The AT 1a -receptor subtype is expressed in rat vascular tissues 21 and seems to mediate Ang II contractile effects. In order to verify the involvement of classic AT 1 -receptors in angiotensin peptide-induced contraction in rat aorta, we used the peptide antagonist, saralasin. Saralasin strongly blocked Ang II and Ang I contractile effects in isolated rat aorta rings.The lack of complete blockade may be due to the partial agonist properties of saralasin at AT receptors. 31 Furthermore, saralasin reduced, although with lesser potency, both Ang III and Ang IV contractile effects. These results demonstrate that much of the angiotensin peptide-induced contractile effects are mediated via the AT 1 -receptor subtype. This observation is also supported by the inhibitory effects of losartan on Ang III responses in rat vascular smooth muscle cells 24 and of saralasin on Ang I-induced effects in rat aortic rings. 4 The generally established ranking of the affinity of angiotensin peptides for AT 1 -and AT 2 -receptors is: Ang II>Ang III>Ang IV>Ang I. 32 Although Ang III has been proposed to act on a specific receptor site in the adrenal cortex 10 and on an AT 3 -receptor from a mouse neuroblastoma cell line, 11 it seems to share the same receptors as Ang II, 5, 24 at least in vascular smooth muscle. Ang III is considered to possess the minimum requirements for occupancy and activation of the AT 1 -receptor subtype.This minimum structure, Arg-R 1 -Tyr-R 2 -His-R 3 -Phe, undergoes appropriate folding in order to permit receptor confirmation. 33 On the other hand, it was shown 7 that the contraction mediated by Ang III in rat aortic rings may not be only mediated by AT 1 -receptors. It was hypothesised that AT 2 -receptors may be involved in the contractile process triggered by Ang III, thus acting as an inhibitory factor in the AT 1 -receptor mediated contraction.Adult rat aorta contains a relatively high density (28%~36%) of AT 2 -receptors. 34 In our study, the failure of saralasin to inhibit approximately 35% of Ang III-induced contraction in rat aortic rings suggests that not all the effects are mediated via AT 1 -receptor subtypes.
Ang IV recognises the AT 1 -and AT 2 -receptors with lower affinity than Ang II and, in addition, possess its own receptors, that mediate effects which often oppose those of Ang II. Recent studies show that AT 4 -specific receptors are located on bovine aortic endothelial cells, human collecting duct cells, coronary microvascular endothelial cells, mammalian heart cellular membranes, cultured porcine aortic endothelial cells and porcine lung endothelial cells. 12, 35 Ang IV acts as a vasodilator and increases blood flow in the kidney and the brain via an AT 4 -specific, receptor-mediated pathway. 27 It is thought that Ang IV is the shortest angiotensin fragment to possess agonistic activity at AT 1 -receptors, albeit with far lower affinity. 25 This suggests that the residues Phe 8 and Tyr 4 are extremely important for activation and signalling of the AT 1 -receptor. It was originally considered that the contractile effects of Ang IV in rat aortae are mediated only by AT 1 -receptors. 7 However, the AT 4 site is also present on vascular smooth muscle and endothelial cells, suggesting a role for Ang IV in vascular control. 36, 37 Moreover, our data show that almost 52% of Ang IV-induced contractile effects on rat isolated aortic rings could not be inhibited by pre-treatment with saralasin. Thus, there is new evidence that Ang IV contractile effects in rat aorta are also mediated by receptor subtypes other than AT 1 -receptors.
Ang(1-7) had no significant contractile effects, although it is thought to recognise AT 1 -and AT 2receptors, albeit with lesser affinity than Ang II. In addition, it has its own receptors, AT [1] [2] [3] [4] [5] [6] [7] , that mediate effects which are often opposed to those of Ang II. 9, 13 It is well known that Ang II activates a remarkable spectrum of signalling pathways in vascular smooth muscle cells upon binding to G-proteincoupled AT 1 -receptors. It stimulates a phosphatidylinositol-specific phospholipase C (PLC), leading to the generation of inositol trisphosphate (IP 3 ), and diacylglycerol (DAG), which are involved in intracellular Ca 2+ mobilisation 16 and protein kinase C (PKC) activation, 38 respectively. Besides these important signalling pathways, receptor and non-receptor tyrosine kinases seem to play an important role in the contractile actions of Ang II. 1, 17, [39] [40] [41] It is important to mention that, in rat vascular smooth muscle cells, there are two mechanisms which sequentially contribute to Ang II-induced IP 3 production. In the first 30 seconds after administration of Ang II, IP 3 generation is insensitive to genistein and is inhibited by anti-PLC-β1 antibodies; after 30 seconds, both genistein and anti-PLCγ 1 antibodies reduce IP 3 accumulation. 42 Smooth muscle is known to contain unusually high levels of tyrosine kinase activity. 43 Ang II also stimulates tyrosine phosphorylation of multiple substrates. 44 Many recent data indicate that activation of tyrosine kinases by several different mechanisms contributes to Ang II effects in target cells, e.g. vasoconstriction. 1, 39, 45 This is in accordance with the suggestion that tyrosine kinase activity may participate in the regulation of pharmacomechanical coupling. 18 Tyrosine kinase inhibitors markedly and reversibly inhibit phasic and tonic contractions induced in visceral and vascular smooth muscle by several agonists. Genistein markedly inhibited phasic contractions of guinea pig taenia coli 18 and contractile responses in gastric preparations. 19, 46 Genistein exhibited high specificity for inhibition of smooth muscle tyrosine kinase activity. 19, 47 In rat vascular smooth muscle cells and glomerular mesangial cells, tyrosine phosphorylation of PLCγ1 and production of IP 3 in response to Ang II is dramatically inhibited by tyrosine kinase inhibition using genistein. 17 Furthermore, the actions of Ang II, as well as the contractile actions of a variety of other G-proteincoupled receptor agonists in rat aorta, were inhibited by the tyrosine kinase inhibitor, genistein. 19 In porcine coronary artery strips, genistein (10 µM) inhibited the contractile actions of Ang II. 48 In our study, genistein partially inhibited Ang II-and Ang I-induced contractions. The genistein-induced inhibition was more marked on Ang III effects and especially important on Ang IV-induced contractions. Thus, Ang IV-and Ang III-induced contractions in isolated rat aorta seem to be more dependent on tyrosine kinase activity than those evoked by Ang II or Ang I. It is known that the maximal inhibitory effects for genistein on tyrosine kinases are obtained with doses of 100-300 µM, after pretreatment for 45-60 minutes. 49 The concentration of genistein used in the present study is entirely in agreement with the in vitro concentration range for inhibition of tyrosine kinase activity, and in accordance with the estimated IC 50 values. 47 The genistein analogue, daidzein, which is inactive as a tyrosine kinase inhibitor, did not significantly affect the contractile effects of any of angiotensin peptides tested. These results suggest that the inhibition of the effects of angiotensin peptides actions by genistein is mediated by inhibition of endogenous tyrosine kinase activity. Furthermore, our data suggest that the type and/or intensity of tyrosine kinase activity differ according to the angiotensin peptides used and the receptor types activated in rat aorta.
Generally, tyrosine kinase activation is highly dependent on extracellular Ca 2+ . 20, 40, 41, 48, 50 The AT 1receptor uses PYK2, a recently identified Ca 2+ -sensitive tyrosine kinase in vascular smooth muscle cells. 40 In cultured vascular smooth muscle cells, 51 Ang II-induced activation of tyrosine kinases has been shown to be dependent on Ca 2+ . Ang II has been shown to cause a rapid and transient elevation of cytosolic Ca 2+ , released from the IP 3 -sensitive intracellular stores by the activation of PLC. This is followed by a sustained elevation of cytosolic Ca 2+ through its influx mediated by an L-type Ca 2+ channel. 52 Other reports showed that Ang IIinduced contraction is highly dependent on extracellular calcium. Thus, it was demonstrated that organic Ca 2+ entry blockers, such as nifedipine, completely inhibited that part of the Ang IIinduced contraction of rat aorta which was dependent upon extracellular Ca 2+ . 53 Ang II may stimulate the voltage-gated Ca 2+ channels of vascular smooth muscle cells through tyrosine protein kinase activation, under conditions that probably exclude participation of PKC. 41 We therefore tested the influence of nifedipine on angiotensin peptide-induced contractions. As already shown, nifedipine pre-treatment potently inhibited Ang IV-induced contractions. At the same time, nifedipine significantly inhibited Ang III contractile effects as compared with those of Ang II and Ang I. We further observed a close relationship between the extracellular calcium influx and tyrosine kinase phosphorylation activity under the stimulatory effects of angiotensin peptides.
We also tested the actions of angiotensin peptides on rat aortic rings in Ca 2+ -free buffer, in the presence and absence of genistein.All angiotensin peptides tested induced phasic contractions in Ca 2+ -free Krebs-Henseleit solution, although of low intensity. Genistein did not significantly influence these contractile effects.Thus, it appears that Ca 2+ influx, rather than the release of Ca 2+ from IP 3sensitive stores, may play a major role in angiotensin peptide-induced contractile effects in rat aorta through tyrosine kinase activation.
Nevertheless, the possibility of a direct blocking action of genistein on Ca 2+ channels cannot be excluded. It was demonstrated that genistein may inhibit L-type Ca 2+ channel currents in vascular smooth muscle cells, 49 in freshly-isolated uterine smooth muscle cells obtained from rats in late pregnancy, 54 as well as the calcium influx in bombesin-stimulated fibroblasts 55 or to attenuate agonist-induced Ca 2+ entry in human platelets. 56 One argument against a direct action of genistein on the Ca 2+ channel itself, is that the K + -induced contraction (depolarisation) in rat aorta was not markedly affected. These results are in agreement with those obtained in guinea pig microvessels. 18 A second argument is the different inhibitory effects of genistein on angiotensin peptideinduced contractions. In the case of a direct action of genistein on the Ca 2+ channel itself, the genistein inhibitory effects would be the same, despite the angiotensin peptide used.
Thus, the inhibitory effects of genistein are probably due to inhibition of smooth muscle tyrosine kinase activity and suppression of protein tyrosine phosphorylation. Although elevation of intracellular Ca 2+ per se may directly activate Ca 2+sensitive tyrosine, 20 a potential role for tyrosine kinase activity in the process of calcium entry is suggested. We cannot exclude a mechanism through which Ca 2+ , released from intracellular stores, activates a Ca 2+ -dependent protein tyrosine kinase, which in turn activates membrane Ca 2+ channels. Thus, an elevation of intracellular calcium via tyrosine kinase-mediated processes may mediate the actions of G-protein-coupled receptor agonists in smooth muscle, including angiotensin peptides.
